Death-Associated Protein Kinase Loss of Expression Is a New Marker for Breast Cancer Prognosis

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3124-3130

  Lévy, Delphine ^a   Plu Bureau, Geneviève ^a   Decroix, Yves ^a   Hugol, Danielle ^a   Rostène, William ^b   Kimchi, Adi ^c   Gompel, Anne ^a,b  

^a HÔTEL DIEU   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ANTIESTROGEN; DEATH ASSOCIATED PROTEIN KINASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; TAMOXIFEN; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST; BREAST NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 2442558057     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0213     Document Type: Article

References (21)

1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003;97: 3133-275.
2. Gompel A, Somaï S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells. Steroids 2000;65:593-8.
3. Darzynkiewicz Z. Apoptosis in antitumor strategies:. modulation of cell cycle or differentiation. J Cell Biochem 1995;58:151-9.
4. Falette N, Paperin MP, Treilleux I, et al. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998;58:1451-5.
5. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the γ interferon-induced cell death. Genes Dev 1995;9: 15-30.
6. Cohen O, Kimchi A. DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ 2001;8:6-15.
7. 2+/calmodulin-dependant, cytoskeletal associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 1997;16: 998-1008.
8. Kissil JF, Feinstein E, Cohen O, et al. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 1997;15:403-7.
9. Ng MHL, To KW, Lo KW, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001;7:1724-9.
10. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature (Lond) 1997;390:180-4.
11. Gompel A, Malet C, Spritzer P, et al. Progestin effect on cell proliferation and 17 β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63: 1174-80.
12. 1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9.
13. Kandouz M, Siromachkova M, Jacob D, et al. Antagonism between estradiol and progestin on Bcl-2 expression in breast cancer cells. Int J Cancer 1996;68:120-5.
14. Malet C, Gompel A, Yaneva H, et al. Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies. J Clin Endocrinol Metab 1991;73:8-17.
15. Somaï S, Chaouat M, Jacob D, et al. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int J Cancer 2003;105:607-12.
16. Lehmann U, Celikkaya G, Hasemeier B, Länger F, Kreipe H. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 2002;62:6634-8.
17. Simpson DJ, Clayton RN, Farrell WE. Preferential loss of death associated protein kinase expression in invasive pituitary tumors is associated with either CpG island methylation or homozygous deletion. Oncogene 2002;21:1217-24.
18. Raveh T, Droguett G, Horwitz MS, De Pinho RA, Kimchi A. DAP-kinase activates p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001;3:1-7.
19. Wang W-J, Kuo J-C, Yao C-C, Chen R-H. DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 2002;159:169-79.
20. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (Bethesda) 2000;92: 1511-6.
21. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-53.